Risankizumab, a high-affinity monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), is steadily gaining traction in the treatment landscape of immune-mediated diseases. Although widely approved for psoriasis, psoriatic arthritis, and Crohn’s disease, its role in Ulcerative Colitis (UC) is under active evaluation. By selectively i
1 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Single-incision Laparoscopy for Gastrostomy
407 Reached2 Comments1 Likes
Intestinal Obstruction and Ileocolic Fistula due to Gossypiboma
861 Reached30 Comments15 Likes
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes